Efficacy and Safety of Hydrogen Therapy in Patients with Early-Stage Interstitial Lung Disease: A Single-Center, Randomized, Parallel-Group Controlled Trial.
Chang Tang, Lanting Wang, Zihua Chen, Jin Yang, Haiqing Gao, Chenggong Guan, Qiaozhi Gu, Shan He, Fanping Yang, Shengan Chen, Li Ma, Zhen Zhang, Ying Zhao, Lin Tang, Yu Xu, Yue Hu, Xiaoqun Luo · Therapeutics and clinical risk management · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 87 patients with early-stage ILD, a significant decrease in CPI and improvement in DLCO-sb were observed in the hydrogen group compared with those in the control group. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in 87 patients with early-stage ILD. A significant decrease in CPI and improvement in DLCO-sb were observed in the hydrogen group compared with those in the control group.
What the Researchers Studied
The researchers studied 87 patients with early-stage ILD. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 1.6 mg/L H₂; Source-reported hydrogen exposure: 1.6 mg/L H₂. A significant decrease in CPI and improvement in DLCO-sb were observed in the hydrogen group compared with those in the control group. The authors concluded that hydrogen therapy exhibits superior efficacy and acceptable safety compared with NAC therapy in patients with early-stage ILD. This provides a new perspective for the treatment of ILD, as an effective block in the early inflammatory stage, where hydrogen molecules can prevent irreversible pulmonary fibrosis and improve the prognosis.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 87 patients with early-stage ILD. The reported sample size was 87. The study used a randomized human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 1.6 mg/L H₂. The source-reported hydrogen exposure was 1.6 mg/L H₂.
Limitations and Safety
Reported limitations: Finally, the relatively small sample size of this trial may have decreased the power of the conclusions.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.